PANKU-Breast01 at #ESMO26: izalontamab brengitecan, an EGFR×HER3 bispecific ADC, doubled PFS vs physician's-choice chemo in pretreated HR+/HER2- MBC (8.2 vs 4.0 mo, HR 0.41). A new

Carmen Criscitiello· @CarmenCriscit · X·2026-10-23 21:35· 2 days agoScore70

Body

PANKU-Breast01 at #ESMO26: izalontamab brengitecan, an EGFR×HER3 bispecific ADC, doubled PFS vs physician's-choice chemo in pretreated HR+/HER2- MBC (8.2 vs 4.0 mo, HR 0.41). A new target pairing after CDK4/6 - promising, though a Chinese-only population. #ESMOAmbassadors @myESMO

166 views · 2 likes · 0 reposts · 0 replies

Conference abstracts

LBA50matched by Proffered paper 1: Breast cancer, early and advanced stage

PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)

https://esmocongress.esmo.org

Source: Carmen Criscitiello · x.com